Inmagene’s Tavalisse First Prescribed in China for ITP Treatment
China-based Inmagene Biopharmaceuticals has announced that its in-licensed drug Tavalisse (fostamatinib) has been first prescribed...
China-based Inmagene Biopharmaceuticals has announced that its in-licensed drug Tavalisse (fostamatinib) has been first prescribed...
Sino-US liver therapy developer AusperBio has announced the initiation of the first cohort dosing in...
The second plenary session of the 20th Communist Party of China (CPC) Central Committee has...
China-based BrightGene Bio-Medical Technology Co., Ltd (SHA: 688166) has received marketing approval from the National...
UK-based abcam (NASDAQ:ABCM) has announced a licensing agreement with China-headquartered MEDx Translational Medicine Co., Ltd,...
US-based Inovio Pharmaceuticals (NASDAQ: INO) and China-based ApolloBio Corp. (NEEQ:430187) have announced positive data from...
Shanghai’s Sunshine Medical Procurement All-In-One (SMPA) platform has revealed the resultant winning bids and spare...
Neo Modulus, a developer of regenerative implantable medical devices based in Suzhou, has reportedly raised...
Takeda Pharmaceutical Co., Ltd has announced the first prescription of its lung cancer therapy Exkivity...
Seven companies have been awarded scientific and technological innovation duty-free import qualification designations by the...
Harbour BioMed (HKG: 2142), a biotech company operating out of the United States, the Netherlands,...
The US Department of Commerce (DOC)’s Bureau of Industry and Security (BIS) has added 37...
Sanyou Biopharmaceuticals, a leading provider of biotech CRDMO services, is set to open a new...
French pharmaceutical major Sanofi (NASDAQ: SNY) has announced that it has received priority review status...
Premier Li Keqiang delivered his annual Government Work Report at the “Two Sessions” meeting, which...
Eli Lilly & Co’s (NYSE: LLY) Retevmo (selpercatinib) has been officially launched in the Chinese...
QL Biopharm, a Beijing-based developer of Escherichia coli-based protein drugs, has reportedly raised RMB 100...
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced that it has received clinical...
Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced that it has received marketing approval from the...
Siyi Intelligence, a developer of soft rehabilitation robots based in Shanghai, has reportedly raised close...